Rapid and sensitive method for quantification of gestodene in human plasma as the oxime derivative by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and its application to bioequivalence study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 945-946, Issue , 2014, Pages 240-246

  Saxena, Ashish ^a,b   Gupta, Arun ^b   Kasibhatta, Ravisekhar ^a   Bob, Manoj ^a   Kumar, V Praveen ^a   Purwar, Bipin ^a  

^a LUPIN LIMITED   (India)

^b Pacific Academy of Higher Education and Research   (India)

Author keywords

Gestodene; Human plasma; Hydroxylamine; LC MS MS; Oxime derivative

Indexed keywords

AMINES; CHROMATOGRAPHY; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHASE SEPARATION;

CHROMATOGRAPHIC SEPARATIONS; GESTODENE; HUMAN PLASMAS; HYDROXYLAMINE; LC-MS/MS; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (LC MS/MS); MASS SPECTROMETRIC DETECTION; SENSITIVE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY;

PLASMA (HUMAN);

GESTODENE; GESTODENE D6; HYDROXYLAMINE; OXIME DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOEQUIVALENCE; CHROMATOGRAPHY; CONTROLLED STUDY; DERIVATIZATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; FEMALE; FREEZE THAWING; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QUANTITATIVE STUDY; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

GESTODENE; HUMAN PLASMA; HYDROXYLAMINE; LC-MS/MS; OXIME DERIVATIVE;

CHROMATOGRAPHY, LIQUID; CONTRACEPTIVES, ORAL, SYNTHETIC; FEMALE; HUMANS; LIMIT OF DETECTION; NORPREGNENES; OXIMES; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 84890813378     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2013.12.003     Document Type: Article

References (14)

1. Pollow K., Juchem M., Grill H.J., Elger W., Beier S., Henderson D., Schmidt-Gollwitzer K., Manz B. Contraception 1989, 40(3):325.
2. Junior E.A., Duarte L.F., Pirasol Vanunci M.L., Teixeira M.L. J. Bioequiv. Availab. 2011, 3(1):6.
3. Kalhorn T.F., Page S.T., Howald W.N., Mostaghel E.A., Nelson P.S. Rapid Commun. Mass Spectrom. 2007, 21(19):3200.
4. Liu S., Sjovall J., Griffiths W.J. Rapid Commun. Mass Spectrom. 2000, 14(6):390.
5. O'Brien Z., Post N., Brown M., Madan A., Coon T., Luo R., Kohout T.A. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877(29):3515.
6. Regal P., Vazquez B.I., Franco C.M., Cepeda A., Fente C. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877(24):2457.
7. Kushnir M.M., Rockwood A.L., Roberts W.L., Pattison E.G., Owen W.E., Bunker A.M., Meikle A.W. Clin. Chem. 2006, 52(8):1559.
8. Licea-Perez H., Wang S., Szapacs M.E., Yang E. Steroids 2008, 73(6):601.
9. Griffiths W.J. Mass Spectrom. Rev. 2003, 22(2):81.
10. Matejicek D., Kuban V. Anal. Chim. Acta 2007, 588(2):304.
11. Nieuweboer B., Tack J., Tauber U., Humpel M., Wendt H. Contraception 1989, 40(3):313.
12. Xiong Z., Sun X., Huo T., Li N., Zheng Y., Sun Y. Clin. Chem. 2006, 52(8):1559.
13. Guidance for Industry: Bioanalytical Method Validation 2001, May, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER).
14. Guideline on Bioanalytical Method Validation. EMEA/CHMP/EWP/192217/2009 2011, Committee for Medicinal Products for Human Use (CHMP).